Navigation Links
New Data Showed Minimal Potential for Drug Interaction Between Cholesterol Drug LIVALO® and a Common Antiretroviral Therapy
Date:7/18/2011

MONTGOMERY, Ala. and INDIANAPOLIS, July 18, 2011 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company (NYSE: LLY) today released new study results that investigated the potential interaction of cholesterol drug LIVALO (pitavastatin) 4 mg in healthy volunteers taking the protease inhibitor (PI) combination lopinavir/ritonavir, a fixed dose combination drug for the treatment of HIV infection.(1)  Protease inhibitors are commonly used antiretroviral HIV medications.(2)  The study, presented at the 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Rome, Italy, found that when co-administered, the individual drug blood levels for LIVALO or each of the PIs was minimally affected.  Based on these data from this FDA-mandated phase IV study, the United States Food and Drug Administration recently approved a labeling change to delete the lopinavir/ritonavir limitation of use from the U.S. LIVALO labeling.

(Logo:  http://photos.prnewswire.com/prnh/20100621/NY23523LOGO)

"HIV is a chronic illness today, as opposed to 30 years ago, and patients with HIV are faced with additional challenges concerning dyslipidemia, accentuated by both the disease process as well as antiretroviral therapies. Additionally, these patients are frequently on multiple medications and the management of dyslipidemia can be even more of a challenge. We are pleased with the results of this study and the absence of a significant drug interaction when LIVALO is co-administered with this combination of protease inhibitors," said Craig Sponseller, MD, Vice President of Medical Affairs, Kowa Pharmaceuticals America, Inc.  

The study was designed to assess the pharmacokinetic (PK) interaction, or effect on overall exposure in the body, of th
'/>"/>

SOURCE Kowa Pharmaceuticals America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
2. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
3. New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
4. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
5. New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
6. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
7. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
8. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
9. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
10. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
11. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and LONDON , August 28, ... approach seamlessly connects people, ... improving outcomes and the cost ... PHG AEX: PHIA) today announced its presence at  ESC ... cardiology solutions, including Heart Model A.I. , EchoNavigator and IntelliSpace ...
(Date:8/27/2015)... CUPERTINO, Calif. , Aug. 27, 2015 ... management is scheduled to present at three upcoming healthcare ... , President and CEO, will present at the Rodman ... 10:00 a.m. Eastern time. The conference is being held ... York City . A live audio webcast of ...
(Date:8/27/2015)... Aug. 27, 2015  Eli Lilly and Company (NYSE: ... Healthcare Conference on Thursday, September 17, 2015. Sue ... Lilly Oncology and Richard Gaynor , M.D., senior ... Lilly Oncology, will participate in a fireside chat at ... live audio webcast will be available on the "Webcasts ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4DURECT to Participate in Upcoming Healthcare Conferences 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... Parkinson,s Disease, ... Decision Resources, WALTHAM, Mass., Aug. 13 Decision ... focusing on pharmaceutical and,healthcare issues, finds that 61 percent ... drug treatment in the first year of,diagnosis. According to ...
... VIENNA, Va., Aug. 14 CEL-SCI CORPORATION,(Amex: ... an agreement with a,biomedical real estate group under which ... for its cancer drug Multikine(R). The,financial value of this ... located near Baltimore, Maryland. Once fully built out to ...
Cached Medicine Technology:Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis 2Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis 3CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 2CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 3CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 4
(Date:8/30/2015)... ... August 31, 2015 , ... Avid collector Andrew Hawley ... Doors Shrine Auditorium concert posters. This hand colored artwork is one of the most ... Los Angles. Hawley states, "When the doors played the Shrine, the band was ...
(Date:8/30/2015)... ... August 31, 2015 , ... ChopChop Kids, the nonprofit publisher ... recently elected two new officers to serve on the organization’s Board of Directors ... and teaching kids to cook real food with their families and help continue ...
(Date:8/30/2015)... ... August 30, 2015 , ... Scientists in France say asbestos exposure ... of digestive cancers. Surviving Mesothelioma has just posted an article on the new research. ... Caen measured the cancer incidence among 2,024 French asbestos plant workers from 1978 to ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional Products International ( ... to Executive Assistant to CEO Mitch Gould for Nutritional Products International. Through ... goals. Kathleen graduated from Florida State University with a Bachelor of Science ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, Diane ... Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your Health.” ... through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 E ...
Breaking Medicine News(10 mins):Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 2Health News:ChopChop Kids Appoints New Chair and Vice-Chair to Board of Directors 3Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2
... likely woman was first infected with dangerous germ, , , WEDNESDAY, ... their food and more with their pets, but one thing ... is a drug-resistant staph infection. , However, according to a ... England Journal of Medicine , a German family appears to ...
... Public Understanding of a,21st Century Epidemic, ... of the,population, experts warn that Alzheimer,s disease ... and unsustainable burdens in,terms of health care ... lost to a devastating disease., (Photo: ...
... 2008, LANCASTER, Pa., March 12 Herley Industries,Inc. ... the second quarter,ended February 3, 2008., Net sales ... $34.7 million. Net loss for the period was approximately ... Company,s Chairman and CEO, will host a conference call,on ...
... 3 and Turmeric ... Supplement, LEXINGTON, ... the latest addition to their family of joint,relief products, which can be ... formula containing Omega 3 and,Turmeric for double strength joint relief., Over ...
... Caregivers were stressed, ate poorly, study found , , WEDNESDAY, March ... serious heart problem may raise your own risk of cardiac ... than 500 family members and others caring for a heart ... of the time were more likely to show psychological strain ...
... novel aerosol version of the most common tuberculosis ... an oral mist, offers significantly better protection against ... dose of the traditional injected vaccine, researchers report ... Academy of Sciences. , The aerosol vaccine -- ...
Cached Medicine News:Health News:Woman and Cat Shared 'Super Bug' 2Health News:Woman and Cat Shared 'Super Bug' 3Health News:New Tools Boost Alzheimer's Awareness 2Health News:New Tools Boost Alzheimer's Awareness 3Health News:Herley Reports Second Quarter Results 2Health News:Herley Reports Second Quarter Results 3Health News:Herley Reports Second Quarter Results 4Health News:Herley Reports Second Quarter Results 5Health News:Herley Reports Second Quarter Results 6Health News:Herley Reports Second Quarter Results 7Health News:Herley Reports Second Quarter Results 8Health News:Herley Reports Second Quarter Results 9Health News:Herley Reports Second Quarter Results 10Health News:The Makers of Conquer HA(TM) Launch All-Natural Double Strength Anti- Inflammatory Formula 2Health News:Caring for Heart Patients Can Strain Hearts 2Health News:Caring for Heart Patients Can Strain Hearts 3Health News:Inhaled tuberculosis vaccine more effective than traditional shot 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... a monopolar cautery connector extending from the ... used for electrosurgery when properly attached to ... ,Ethicon Endo-Surgery provides disposable handheld instruments ... Our handheld instruments come in 5mm and ...
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: